dna
vaccin
express
codonoptim
venezuelan
equin
enceph
viru
veev
ebola
viru
ebov
glycoprotein
gene
provid
protect
immun
mice
nonhuman
primat
deliv
intramuscular
im
electropor
ep
achiev
equival
protect
efficaci
absenc
ep
evalu
veev
ebov
dna
vaccin
construct
use
minim
nanoplasmid
express
vector
smaller
convent
plasmid
use
dna
vaccin
vector
may
also
design
coexpress
type
interferon
induc
innat
immun
agonist
gene
adjuv
effect
nanoplasmid
vaccin
mice
increas
antibodi
respons
compar
receiv
convent
vaccin
deliv
im
inject
respons
enhanc
inclus
innat
immun
agonist
gene
nanoplasmid
veev
dna
vaccin
also
significantli
increas
protect
aerosol
veev
challeng
compar
veev
dna
vaccin
although
mice
receiv
nanoplasmid
ebov
dna
vaccin
dose
test
surviv
ebov
challeng
mice
receiv
nanoplasmid
ebov
dna
vaccin
coexpress
innat
immun
agonist
gene
fail
lose
weight
challeng
result
suggest
nanoplasmid
vector
improv
immunogen
protect
efficaci
alphaviru
filoviru
dna
vaccin
despit
abil
trigger
potent
innat
adapt
immun
respons
widespread
use
dna
vaccin
hamper
logist
requir
special
method
electropor
ep
effect
deliveri
deliveri
method
requir
special
train
advanc
technolog
access
sustain
power
sourc
pose
signific
challeng
remot
area
enact
ring
vaccin
strategi
outbreak
set
simpler
approach
dna
vaccin
deliveri
provid
protect
efficaci
compar
ep
could
advantag
broader
applic
platform
one
possibl
approach
improv
dna
vaccin
immunogen
modifi
dna
vaccin
backbon
includ
modif
promot
enhanc
antigen
express
remov
antibiot
select
marker
elimin
nonfunct
sequenc
limit
express
natur
technolog
corpor
ntc
test
approach
develop
minim
nanoplasmid
express
vector
vector
smaller
tradit
dna
vaccin
plasmid
allow
improv
uptak
persist
transfect
cell
larg
extragen
region
bacteri
dna
also
mediat
transgen
silenc
certain
tissu
phenomenon
may
avoid
use
shorter
dna
sequenc
subsequ
lead
increas
transgen
express
yield
enhanc
immun
respons
sustain
improv
immunolog
memori
ntc
also
design
nanoplasmid
vector
coexpress
innat
immun
immunostimulatori
rna
isrna
agonist
function
type
interferonab
ifnab
induc
genet
adjuv
vector
coexpress
retino
acidinduc
gene
rigi
doublestrand
rna
dsrna
agonist
ntcerna
dsrna
rigi
agonist
well
tolllik
receptor
stimul
cpg
motif
ntcernacpg
ifnab
power
genet
adjuv
enhanc
cellular
humor
respons
ntc
previous
test
influenza
hemagglutinin
ha
vaccin
express
ntcerna
vector
vaccin
ntcernaha
vaccin
significantli
improv
antibodi
titer
antibodi
bind
avid
compar
standard
ntc
ha
vector
addit
ifnab
requir
optim
dna
vaccin
immunogen
inclus
ifnab
stimul
agonist
may
compens
reduct
immunogen
dna
vaccin
deliv
absenc
ep
laboratori
develop
evalu
dna
vaccin
sever
highli
pathogen
biodefenserel
target
includ
alphaviru
venezuelan
equin
enceph
viru
veev
natur
mosquitoborn
transmiss
veev
human
result
sever
neurolog
diseas
aerosol
veev
infect
may
yield
increas
morbid
mortal
compar
observ
natur
infect
previous
demonstr
candid
veev
dna
vaccin
pwrgveev
express
codonoptim
envelop
glycoprotein
gp
gene
deliv
intramuscular
im
ep
elicit
robust
veevspecif
immun
respons
protect
mice
nonhuman
primat
nhp
aerosol
veev
challeng
subsequ
pwrgveev
vaccin
candid
prove
safe
highli
immunogen
phase
clinic
studi
subject
develop
veevneutr
antibodi
follow
imep
deliveri
also
previous
develop
test
candid
zair
ebolaviru
ebov
gp
dna
vaccin
pwrgebov
deliv
imep
dna
vaccin
elicit
protect
immun
im
ebov
challeng
mice
nhp
pwrgebovvaccin
nhp
develop
prechalleng
ebovneutr
antibodi
well
high
number
ebovspecif
cell
data
suggest
dna
vaccin
may
effect
mean
elicit
protect
immun
filoviru
infect
cellmedi
humor
immun
respons
like
requir
protect
ebov
challeng
explor
potenti
benefit
nanoplasmid
vector
engin
express
codonoptim
veev
ebov
gp
gene
without
coexpress
innat
immun
agonist
specif
evalu
immun
respons
protect
efficaci
elicit
vaccin
candid
follow
im
inject
murin
model
result
suggest
potenti
path
forward
veev
ebov
nanoplasmid
dna
vaccin
deliv
im
inject
absenc
ep
previou
report
suggest
nanoplasmid
vector
improv
express
level
durat
express
compar
convent
plasmid
use
dna
vaccin
examin
context
veev
ebov
nanoplasmid
construct
compar
transient
vitro
antigen
express
variou
nanoplasmid
vector
standard
vector
cell
transfect
ng
individu
nanoplasmid
construct
standard
vaccin
plasmid
cell
harvest
h
transfect
analysi
antigen
express
level
flow
cytometri
dna
concentr
test
transfect
variou
nanoplasmid
construct
result
significantli
increas
percentag
veev
veev
ebov
gp
cell
compar
transfect
cell
figur
determin
whether
increas
antigen
express
observ
nanoplasmid
construct
persist
longer
period
time
harvest
cell
transfect
ng
individu
nanoplasmid
construct
standard
vaccin
plasmid
variou
time
point
period
day
transfect
analysi
antigen
express
level
flow
cytometri
experi
significantli
increas
percentag
veev
veev
ebov
gp
cell
observ
nanoplasmid
construct
compar
construct
day
posttransfect
figur
repres
histogram
plot
veev
express
shown
figur
nanoplasmid
veev
vector
improv
humor
cellular
immun
respons
mice
evalu
potenti
immunolog
benefit
nanoplasmid
veev
construct
vaccin
group
balbc
mice
two
time
week
apart
im
inject
either
pwrgveev
dna
vaccin
variou
nanoplasmid
veev
dna
vaccin
describ
materi
method
vaccin
ntcveev
construct
result
slightli
improv
statist
similar
total
immunoglobulin
g
igg
antiveev
antibodi
level
compar
observ
mice
receiv
pwrgveev
vaccin
figur
contrast
ntcveev
construct
ad
isrna
rigi
agonist
yield
signific
increas
total
igg
titer
howev
addit
inclus
cpg
motif
within
construct
boost
total
igg
respons
compar
ntcerna
veev
vaccin
although
statist
signific
vaccin
ntcernaveev
ntcernacpgveev
construct
also
result
subtyp
antibodi
titer
trend
slightli
higher
pwrgveev
standard
ntc
veev
construct
figur
moreov
vaccin
isrnaexpress
nanoplasmid
trend
toward
slightli
enhanc
veevneutr
antibodi
gener
suggest
broad
improv
humor
respons
figur
unlik
antibodi
respons
observ
littl
discern
differ
cellmedi
immun
elicit
vaccin
mice
receiv
either
pwrgveev
variou
nanoplasmid
veev
dna
vaccin
display
similar
number
veev
ifng
figur
cell
figur
quantifi
elispot
note
group
vaccin
veev
dna
vaccin
deliv
im
inject
develop
humor
cellmedi
immun
respons
equival
observ
pwrgveev
imep
control
group
succumb
diseas
euthan
accord
earli
endpoint
criteria
day
postinfect
figur
mice
vaccin
pwrgveev
ntcveev
construct
exhibit
surviv
respect
follow
viral
challeng
repres
signific
improv
rel
empti
vector
control
mice
howev
pwrgveev
ntcveev
group
exhibit
similar
level
weight
loss
neg
control
mice
follow
challeng
protect
enhanc
mice
receiv
either
ntcernaveev
ntcernacpgveev
dna
vaccin
surviv
rate
observ
group
addit
mice
group
exhibit
less
postchalleng
weight
loss
compar
im
vaccin
group
observ
previous
mice
imep
control
display
clinic
sign
diseas
postchalleng
surviv
protect
observ
group
also
significantli
higher
im
vaccin
group
sinc
vaccin
nanoplasmid
vector
improv
protect
efficaci
veev
vaccin
context
im
deliveri
absenc
ep
expand
studi
evalu
benefit
nanoplasmid
vector
vaccin
ebov
observ
signific
differ
immunogen
protect
efficaci
ntcernaveev
ntcernacpgveev
vaccin
chose
includ
ntcernacpgebov
vaccin
studi
vaccin
group
balbc
mice
two
time
week
apart
im
inject
pwrgebov
ntcebov
ntcernacpgebov
vaccin
describ
materi
method
observ
veev
studi
vaccin
ntc
ebov
result
slightli
improv
statist
similar
total
igg
antiebov
antibodi
level
compar
mice
receiv
pwrgebov
vaccin
figur
also
mirror
veev
result
addit
innat
immun
stimul
ernacpg
motif
ntcebov
dna
vaccin
significantli
improv
total
igg
respons
also
observ
slight
increas
ebovneutr
antibodi
titer
nanoplasmid
vaccin
antibodi
product
ntcernacpgebov
group
although
statist
signific
level
figur
vaccin
ebov
nanoplasmid
also
improv
ebovspecif
ifng
cell
respons
quantifi
elispot
figur
veev
group
vaccin
im
inject
approach
immunogen
level
measur
pwrgebov
imep
control
group
day
second
vaccin
remain
mice
challeng
pfu
maebov
intraperiton
ip
inject
mice
empti
vector
control
group
exhibit
clinic
sign
diseas
includ
sever
weight
loss
ruffl
fur
succumb
diseas
euthan
accord
earli
endpoint
criteria
day
postinfect
contrast
mice
group
femal
balbc
mice
vaccin
mg
pwrgveev
variou
veev
nanoplasmid
day
im
inject
veev
gpspecif
total
igg
antibodi
titer
b
c
subtyp
titer
quantifi
elisa
sera
collect
day
second
vaccin
psvna
neutral
titer
vaccin
mice
also
determin
use
sera
sampl
data
repres
group
mean
averag
sem
p
p
p
p
valu
determin
oneway
anova
tukey
post
hoc
test
receiv
either
pwrgebov
ntcebov
ntcernacpgebov
vaccin
surviv
viral
challeng
figur
interestingli
mice
receiv
ntcernacpgebov
fail
lose
weight
follow
viral
challeng
figur
ebov
vaccin
mice
surviv
viral
challeng
next
quantifi
antinucleoprotein
np
serum
antibodi
respons
follow
ebov
challeng
attempt
indirectli
determin
potenti
differ
abil
immun
respons
elicit
vaccin
differ
group
control
viral
replic
howev
mice
surviv
ebov
challeng
exhibit
similar
level
antinp
igg
data
shown
major
advantag
dna
vaccin
abil
elicit
high
level
humor
cellular
immun
respons
make
dna
vaccin
ideal
platform
elicit
protect
immun
variou
pathogen
previous
demonstr
vaccin
codonoptim
veev
gp
ebov
gp
dna
vaccin
could
protect
mice
nhp
viral
challeng
deliv
imep
goal
studi
present
determin
whether
nextgener
minim
dna
vaccin
plasmid
express
ifnab
stimul
innat
immun
agonist
could
enhanc
humor
andor
cellmedi
immun
respons
elicit
follow
im
deliveri
absenc
ep
mice
knowledg
first
report
examin
approach
biodefenserel
pathogen
initi
found
variou
nanoplasmid
vector
improv
vitro
veev
ebov
antigen
express
compar
vector
use
equal
dna
concentr
howev
improv
antigen
product
seem
signific
impact
shortterm
vaccin
immunogen
ntc
veev
ntcebov
vaccin
elicit
compar
immun
respons
respect
vaccin
instead
appear
inclus
isrna
innat
immun
agonist
greatest
influenc
vaccin
immunogen
despit
group
femal
balbc
mice
vaccin
mg
pwrgveev
variou
veev
nanoplasmid
day
im
inject
euthan
day
isol
splenocyt
splenocyt
stimul
pool
overlap
peptid
span
veev
protein
veev
b
ifng
cell
c
cell
quantifi
via
elispot
data
repres
group
mean
averag
sem
p
p
valu
determin
oneway
anova
tukey
post
hoc
test
import
rigi
signal
gener
antigenspecif
cell
measur
signific
increas
number
ifng
cell
either
antigen
agreement
previou
find
isrna
express
enrich
cell
immun
possibl
due
lack
hairpin
structur
dsrna
transcrib
nanoplasmid
convers
inclus
isrna
adjuv
yield
improv
viral
gpspecif
igg
titer
trend
toward
improv
viru
neutral
antibodi
titer
like
due
ifnab
abil
upregul
costimulatori
molecul
prime
cell
drive
subsequ
b
cell
respons
ifnab
also
amplifi
sensit
b
cell
receptor
boost
abil
naiv
b
cell
produc
highaffin
antibodi
somewhat
surprisingli
addit
cpg
motif
limit
effect
veev
dna
vaccin
immunogen
one
possibl
explan
result
limit
effect
signal
dna
vaccin
immunogen
altern
result
may
suggest
peak
respons
achiev
inclus
rigi
agonist
subtl
immun
differ
may
better
discern
lower
vaccin
dose
result
challeng
studi
also
suggest
increas
dna
vaccin
immunogen
afford
nanoplasmid
may
subsequ
enhanc
protect
efficaci
neutral
antibodi
direct
envelop
glycoprotein
wide
accept
correl
protect
veev
trend
toward
increas
neutral
measur
ntcernaveev
ntcernacpgveev
vaccin
group
repres
one
possibl
explan
improv
protect
aerosol
veev
challeng
howev
neutral
antibodi
titer
alway
significantli
associ
protect
veev
challeng
aerosol
rout
nonneutr
antibodi
also
proven
effect
prevent
lethal
alphaviru
infect
report
vaccineelicit
ie
h
phenotyp
correl
strongli
protect
aerosol
veev
challeng
effect
may
due
broad
rang
effector
function
antibodydepend
cellular
cytotox
adcc
complement
fixat
coexpress
isrna
nanoplasmid
vector
result
increas
product
albeit
statist
signific
degre
howev
im
vaccin
mice
higher
ratio
appear
better
protect
veev
challeng
figur
suggest
improv
level
may
substanti
enough
afford
greater
protect
challeng
taken
togeth
data
combin
improv
neutral
capabl
suggest
isrna
express
nanoplasmid
vector
shape
multipl
facet
adapt
immun
respons
requir
protect
veev
challeng
ebov
nanoplasmid
vaccin
result
similar
immun
profil
observ
veev
studi
vaccin
ntcebov
result
antibodi
respons
trend
higher
quantifi
pwrgebov
group
humor
respons
boost
addit
dsrnacpg
adjuv
notabl
nanoplasmid
vaccin
group
exhibit
higher
level
pwrgebov
group
correl
protect
ebov
remain
unclear
sever
report
detail
role
confer
protect
ebov
challeng
mice
moreov
warfield
et
al
previous
report
ebov
vlp
vaccin
elicit
strong
adcc
activ
vaccin
nhp
followon
studi
suggest
vaccin
elicit
weakli
neutral
highli
protect
h
antibodi
studi
suggest
similar
protect
effect
im
vaccin
mice
higher
ratio
lost
less
weight
follow
challeng
figur
although
abl
quantifi
signific
chang
protect
ebov
challeng
dna
dose
test
noteworthi
nanoplasmid
vaccin
neg
impact
protect
efficaci
fact
sustain
weight
seen
ntcernacpg
ebov
group
suggest
isrna
may
abil
augment
protect
efficaci
beyond
measur
followon
ebov
challeng
studi
perform
use
rang
dna
vaccin
dose
requir
definit
determin
impact
nanoplasmid
vector
platform
overal
result
demonstr
vaccin
nextgener
nanoplasmid
vector
improv
dna
vaccin
immunogen
deliv
simpl
im
inject
absenc
ep
furthermor
inclus
innat
immun
agonist
dsrna
andor
cpg
motif
significantli
boost
protect
efficaci
howev
sever
question
remain
address
futur
studi
interest
abil
nanoplasmid
improv
immunolog
memori
well
abil
spur
affin
matur
previou
report
demonstr
sustain
antigen
product
nanoplasmid
transfect
cell
suggest
effect
possibl
yet
character
outsid
scope
studi
final
group
vaccin
im
inject
gener
immun
respons
equal
elicit
imep
studi
requir
determin
whether
nanoplasmid
vector
suffici
enhanc
dna
vaccin
immunogen
could
offer
protect
immun
nhp
relev
model
human
diseas
construct
pwrgveev
dna
vaccin
candid
express
gene
veev
subtyp
iab
previous
describ
briefli
codonoptim
structur
gene
minu
capsid
protein
code
region
veev
iab
strain
trinidad
donkey
genbank
accomplish
use
gene
optim
bioinformat
algorithm
follow
synthesi
codonoptim
gene
geneart
regensburg
germani
pwrgveev
construct
clone
synthes
codonoptim
gene
noti
bglii
restrict
site
downstream
cytomegaloviru
immediateearli
promot
pwrg
ebov
dna
vaccin
plasmid
construct
similar
manner
insert
codonoptim
gp
gene
geneart
regensburg
germani
ebovkikwit
genbank
eukaryot
express
vector
describ
previous
codonoptim
ebov
gp
gene
sequenc
result
ablat
genom
edit
motif
ebov
prevent
product
solubl
gp
sgp
nanoplasmid
vaccin
produc
standard
restrict
digestionmedi
transfer
veev
ebov
transgen
nanoplasmid
vector
plasmid
nanoplasmid
express
vector
contain
bacteri
backbon
compris
bp
rnabas
sucros
select
antibiot
free
marker
rnaout
bp
origin
deriv
rna
coexpress
isrna
antigen
rna
transcrib
either
rna
pol
ii
isrna
encod
downstream
transgen
utr
cpg
rna
rna
pol
iii
isrna
transcrib
independ
transgen
bp
rna
pol
iii
converg
transcrib
nonpalindrom
dsrna
base
isrna
activ
rigi
vector
ebov
veev
transgen
express
cmv
promot
upstream
htlvir
express
enhanc
researchgrad
vaccin
plasmid
manufactur
aldevron
fargo
nd
researchgrad
nanoplasmid
vaccin
plasmid
manufactur
natur
technolog
corpor
lincoln
ne
cell
transfect
multipl
concentr
respect
veev
ebov
gp
express
plasmid
use
fugen
hd
promega
madison
wi
accord
manufactur
instruct
cultur
incub
c
indic
time
transfect
cell
harvest
surfac
glycoprotein
express
quantifi
flow
cytometri
quantif
surfac
veev
protein
monoclon
antibodi
use
primari
antibodi
concentr
mgml
veev
surfac
express
quantifi
monoclon
antibodi
concentr
mgml
ebov
gp
quantif
monoclon
antibodi
use
primari
antibodi
concentr
mgml
secondari
antibodi
assay
alexa
fluor
goat
antimous
antibodi
becton
dickinson
franklin
lake
nj
dilut
fac
buffer
sampl
measur
facscalibur
becton
dickinson
franklin
lake
nj
analyz
use
flowjo
softwar
flowjo
ashland
group
femal
balbc
mice
age
old
jackson
laboratori
bar
harbor
anesthet
vaccin
two
time
interv
im
inject
anterior
tibiali
mg
codonoptim
pwrgveev
ntcveev
ntcernaveev
ntcernacpgveev
dna
plasmid
dilut
calciumand
magnesiumfre
pb
neg
control
group
mice
receiv
mg
empti
vector
deliv
im
inject
schedul
posit
control
group
mice
receiv
mg
codonoptim
pwrgveev
dna
plasmid
deliv
imep
imep
mice
anesthet
vaccin
anterior
tibiali
muscl
ml
dna
solut
use
cm
insulin
syring
insert
center
ichor
medic
system
trigrid
electrod
array
san
diego
ca
mm
electrod
space
inject
dna
follow
immedi
electr
stimul
amplitud
vcm
total
durat
ms
ms
interv
sera
collect
prior
vaccin
day
submandibular
bleed
micegroup
euthan
day
splenocyt
isol
cell
analysi
sera
isol
blood
sampl
collect
remain
mice
day
mice
subsequ
challeng
day
target
dose
pfu
veev
iab
strain
trinidad
donkey
via
aerosol
rout
challeng
mice
place
class
iii
biolog
safeti
cabinet
locat
insid
biosafeti
level
contain
suit
expos
wholebodi
aerosol
chamber
veev
aerosol
creat
collison
nebul
min
previous
describ
veev
iab
dilut
appropri
start
concentr
hank
balanc
salt
solut
contain
fetal
bovin
serum
use
aerosol
gener
sampl
collect
allglass
imping
agi
attach
aerosol
chamber
analyz
plaqu
assay
vero
cell
use
standard
method
previous
describ
determin
inhal
dose
veev
mice
monitor
daili
clinic
score
surviv
anim
found
meet
earli
endpoint
criteria
euthan
collect
weight
mice
per
group
measur
daili
day
challeng
surviv
mice
euthan
exsanguin
deep
anesthesia
research
conduct
iacuc
approv
protocol
complianc
anim
welfar
act
ph
polici
feder
statut
regul
relat
anim
experi
involv
anim
facil
research
conduct
accredit
associ
assess
accredit
laboratori
anim
care
intern
adher
principl
state
guid
care
use
laboratori
anim
nation
research
council
group
femal
balbc
mice
age
old
jackson
laboratori
bar
harbor
vaccin
two
time
interv
mice
vaccin
im
inject
receiv
mg
codonoptim
pwrgebov
ntcebov
ntcernacpg
ebov
dna
plasmid
dilut
calciumand
magnesiumfre
pb
neg
control
group
mice
receiv
mg
empti
vector
deliv
im
inject
schedul
posit
control
group
mice
receiv
mg
codonoptim
pwrgebov
dna
plasmid
imep
describ
sera
collect
prior
vaccin
day
submandibular
bleed
mice
per
group
euthan
day
cell
analysi
remain
mice
observ
day
sera
harvest
antibodi
analysi
mice
subsequ
challeng
day
pfu
mouseadapt
ebov
maebov
via
ip
rout
mice
monitor
daili
clinic
score
surviv
collect
weight
mice
per
group
measur
daili
day
follow
challeng
surviv
mice
euthan
exsanguin
deep
anesthesia
high
bind
elisa
plate
corn
corn
ny
coat
viruslik
particl
vlp
express
either
veev
antigen
ebov
gp
antigen
encod
within
dna
vaccin
vlp
produc
cotransfect
plasmid
express
codonoptim
glycoprotein
gene
veev
iab
strain
trinidad
donkey
ebov
gp
strain
kikwit
scaffold
murin
leukemia
viru
mlv
gag
protein
previous
describ
briefli
cell
transfect
pwrgmlv
gag
either
pwrgveev
pwrgebov
cell
supernat
collect
h
posttransfect
pool
clarifi
centrifug
filter
mm
filter
vlp
concentr
centricon
filter
unit
cutoff
emd
millipor
burlington
accord
manufactur
instruct
vlp
pellet
sucros
cushion
viru
resuspens
buffer
vrb
mm
nacl
mm
hepe
ph
centrifug
h
g
rotor
c
vlp
pellet
resuspend
overnight
vrb
c
pool
dilut
vrb
dilut
vlp
repellet
without
sucros
cushion
describ
vlp
resuspend
volum
vrb
rel
start
supernat
store
c
elisa
plate
coat
concentr
ngwell
incub
overnight
c
follow
day
plate
wash
pb
contain
block
neptun
block
immunochemistri
technolog
bloomington
mn
h
c
plate
wash
prior
load
serial
dilut
mous
sera
duplic
dilut
rang
serum
dilut
carri
neptun
block
plate
incub
ambient
temperatur
h
prior
wash
incub
dilut
horseradish
peroxidas
hrp
conjug
goat
antimous
seracar
life
scienc
gaithersburg
md
neptun
block
h
ambient
temperatur
plate
wash
develop
sureblu
tmb
substrat
seracar
life
scienc
gaithersburg
md
absorb
nm
wavelength
detect
tecan
micropl
reader
tecan
group
switzerland
pool
naiv
sera
collect
prior
vaccin
use
intern
control
assay
group
plate
cutoff
valu
determin
base
averag
absorb
pool
preble
sera
respect
group
endpoint
titer
determin
use
graphpad
prism
graphpad
softwar
la
jolla
ca
antibodi
subtyp
elisa
hrpconjug
goat
antimous
antimous
secondari
antibodi
bethyl
laboratori
montgomeri
tx
use
dilut
ebov
nucleoprotein
elisa
plate
coat
recombin
ebov
nucleoprotein
panthera
biopharma
aiea
hi
concentr
mgml
assay
describ
pseudovirion
neutral
assay
psvna
use
detect
neutral
antibodi
sera
describ
previous
use
replicationrestrict
recombin
vesicular
stomat
viru
rvsv
dg
express
luciferas
pseudotyp
either
veev
iab
glycoprotein
trinidad
donkey
ebola
gp
kikwit
briefli
heatinactiv
mous
sera
c
min
first
dilut
follow
serial
dilut
mix
equal
volum
eagl
minimum
essenti
medium
earl
salt
fetal
bovin
sera
contain
fluoresc
focu
unit
veev
ebov
gp
pseudovirion
guinea
pig
complement
cedarlan
burlington
nc
sera
pseudovirion
mixtur
incub
overnight
c
follow
incub
ml
inocul
onto
cell
monolay
clear
bottom
blackwal
plate
duplic
plate
incub
c
h
media
discard
cell
lyse
accord
luciferas
kit
protocol
promega
madison
wi
tecan
pro
tecan
group
switzerland
use
acquir
luciferas
data
valu
graph
use
graphpad
prism
softwar
use
calcul
percent
neutral
normal
cell
alon
pseudovirion
alon
minimum
maximum
signal
respect
percent
neutral
valu
duplic
serial
dilut
plot
psvna
psvna
titer
interpol
curv
geometr
mean
titer
calcul
graphpad
prism
mous
cell
elispot
reagent
obtain
mabtech
cincinnati
oh
antigen
specif
ifng
cell
quantifi
per
manufactur
instruct
posit
control
well
stimul
ngml
phorbol
pma
sigmaaldrich
st
loui
mo
ngml
ionomycin
sigmaaldrich
st
loui
mo
test
splenocyt
well
stimul
appropri
peptid
concentr
mgml
cell
incub
h
c
co
posit
spot
visual
ctl
imag
count
perform
immunospot
softwar
cellular
technolog
shaker
height
oh
splenocyt
veev
vaccin
mice
stimul
pool
peptid
contain
overlap
span
either
veev
iab
envelop
glycoprotein
pepscan
lelystad
netherland
splenocyt
ebov
vaccin
mice
stimul
pool
peptid
contain
overlap
span
envelop
glycoprotein
ebov
mimotop
victoria
australia
data
present
mean
individu
mice
standard
error
mean
sem
statist
analysi
perform
use
student
test
oneway
anova
follow
tukey
posttest
twoway
anova
dunnett
multipl
comparison
test
kaplan
meier
surviv
curv
analysi
use
log
rank
test
perform
determin
p
valu
signific
vaccin
group
surviv
lethal
challeng
compar
control
group
use
graphpad
prism
window
log
transform
appli
vlp
endpoint
elisa
titer
use
graphpad
softwar
describ
supplement
inform
found
onlin
http
jaw
employe
equiti
interest
natur
technolog
corpor
author
acknowledg
potenti
conflict
interest
inher
public
manuscript
assert
effort
reduc
elimin
conflict
made
possibl
remain
author
declar
compet
interest
repres
histogram
plot
gener
cell
transfect
ng
empti
vector
pwrgveev
individu
nanoplasmid
vaccin
repres
plot
percentag
gp
express
cell
determin
stain
veev
surfac
express
monoclon
antibodi
data
repres
shown
figur
c
e
c
femal
balbc
mice
vaccin
pwrgveev
variou
veev
nanoplasmid
day
im
inject
veev
gpspecif
antibodi
respons
analyz
day
second
vaccin
elisa
ratio
veevspecif
antibodi
titer
shown
mice
euthan
succumb
diseas
follow
pfu
veev
aerosol
challeng
shown
red
data
group
mean
averag
sem
femal
balbc
mice
vaccin
pwrgebov
variou
ebov
nanoplasmid
day
im
inject
ebov
gpspecif
antibodi
respons
analyz
day
second
vaccin
elisa
ratio
ebovspecif
antibodi
titer
shown
data
group
mean
averag
sem
